30 days after AMI were analyzed. The primary
end point was 6-month MACEs including death, MI, and revascularization. During
6-month follow-up, 317 patients (3.2%) had MACEs including 66 (0.6%) deaths, 23 (0.2%)
recurrent MIs, and 218 (2.2%) revascularizations. In multivariate logistic regression analysis,
factors reflecting demographics (body mass index), severity of left ventricular systolic
dysfunction (Killip class
I, in-hospital cardiogenic shock, use of intra-aortic balloon
pump), residual myocardial ischemia (previous coronary heart disease, multivessel disease),
and electrical instability (ventricular tachycardia/ventricular fibrillation on admission)
were independent predictors of 6-month MACEs after adjustment for clinical, angiographic,
and procedural data. Plasma level of N-terminal pro–B-type natriuretic peptide
provided an additional prognostic value predicting 6-month MACEs. In conclusion, this study
provides useful prognostic information for clinicians to advise patients who have survived the
acute phase of MI. More intensive management is needed in survivors after MI with these
high-risk features. © 2009 Elsevier Inc. (Am J Cardiol 2009;104:182–189)
